by alfie | May 3, 2024 | news and press
< Back to Sanius content Sanius Health, a London-based RWE Generation Firm and AI-Powered Patient Ecosystem, Pivotal in NICE Approval of Novel Sickle Cell Disease Therapy Voxelotor for NHS use Earlier today, UK-based regulator the National Institute for Health and...
by alfie | Jan 15, 2024 | news and press
< Back to Sanius content Therapeutic Innovation Through Pre-, Peri- and Post-Trial Digitalisation. I have often highlighted this to clinical, industry, and CRO colleagues – maybe to anyone who would listen. Clinical trials are important. They are harder and more...
by alfie | Jan 5, 2024 | news and press
< Back to Sanius content AI platform Sanius Health and primary care provider Modality Partnership announce £225m deal Sanius Health has announced a deal valued at £225 million which will see its data, research and personalised health patient AI platform leveraged...
by alfie | Dec 15, 2023 | study and resources
SICKLE CELL DISEASE Real-Time Vaccination Impacts in Sickle Cell Disease: A Real-World Patient Case Study for Influenza and Covid-19 Vaccination Annual Academy of Sickle Cell and Thalassaemia Conference, ASCAT (2022) Areas of interest /Real-world vaccination impacts...
by alfie | Dec 15, 2023 | study and resources
SICKLE CELL DISEASE Live Outcomes and Biometric Monitoring: Potential Implications For Patient Quality of Life in Sickle Cell Disease 17th Annual Sickle Cell and Thalassaemia Conference (2022) Areas of interest /Approaches to QoL assessment & their impact...